Role of miR-214 in biomaterial transplantation therapy for osteonecrosis

Article type: Research Article

Authors: Wang, Yuying^{a; b} | He, Rui^{b; c} | Yang, Anqi^d | Guo, Rui^a | Liu, Jie^e | Liang, Guoqing^a | Sheng, Donglai^a; | Zhong, Liangjun^{b; c;}

Affiliations: [a] Key Laboratory of Organ Development and Regeneration of Zhejiang Province, College of Life and Environmental Science, Hangzhou Normal University, Hangzhou, China | [b] Department of Stomatology, College of Medicine, Hangzhou Normal University, Hangzhou, China | [c] Department of Stomatology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China | [d] Department of Physiology, College of Medicine, Hangzhou Normal University, Hangzhou, China | [e] Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China

Correspondence: [*] Corresponding authors: Liangjun Zhong and Donglai Sheng, Hangzhou Normal University, No. 2318, Yu Hang Tang Road, Hangzhou, China. Tel.: +86 571 28867022; E-mails: [email protected], [email protected]

Abstract: BACKGROUND:The effectiveness and availability of conservative therapies for osteonecrosis of the femoral head (ONFH) are limited. Transplantation of bone marrow mesenchymal stem cells (BMSCs) combined with Bio-Oss, which is a good bone scaffold biomaterial for cell proliferation and differentiation, is a new potential therapy. Of note, the expression of miRNAs was significantly modified in cells cultured with Bio-Oss, and MiR-214 was correlated positively with osteonecrosis. Furthermore, miR-214 was upregulated in cells exposed to Bio-Oss. OBJECTIVE:To investigate whether targeting miR-214 further improves the transplantation effect. METHODS:We treated BMSCs with agomiR-214 (a miR-214 agonist), antagomiR-214 (a miR-214 inhibitor), or vehicle, followed by their transplantation into ONFH model rats. RESULTS:Histological and histomorphometric data showed that bone formation was significantly increased in the experimental groups (Bio-Oss and BMSCs treated with antagomiR-214) compared with other groups. CONCLUSIONS:miR-214 participates in the inhibition of osteoblastic bone formation, and the inhibition of miR-214 to bone formation during transplantation therapy with Bio-Oss combined with BMSCs for ONFH.

Keywords: Bio-Oss, BMSCs, miR-214, bone regeneration, transplantation therapy

DOI: 10.3233/BME-211296

Journal: Bio-Medical Materials and Engineering, vol. 33, no. 5, pp. 351-364, 2022